Blood glucose levels in patients not hospitalized vaccinated against SARS-CoV-2 viral infection as risk factor for severe Covid-19

Hyperglycemia or diabetic people has been suggested as a risk factor for developing severe illness from coronavirus disease 2019 (COVID-19). The aim of our study was to detect the presence of glucose levels in blood samples of the patients without known pre-existing diabetes collected in the post-pandemic period. Patients with severe COVID-19 pneumonia requiring hospitalization between January 2023 and December 2023 were not enrolled in this retrospective observational study. This is a retrospective epidemiology study involving patients categorized into three groups according to admission Blood Glucose (BG) levels: < 70 mg/dL; 77 – 90 mg/dL; > 99 mg/dL collected in 2023y according to standard glycaemia targets. Throughout 2023y, a total of 13,246 blood samples were collected from 11,425 non-diabetic patients vaccinated against Covid, which 10,478 male and 947 female. Furthermore, we detected that nondiabetic patients with good glycemic control (86.77%). Moreover, we detected highest percentage of samples collected from men (91,71%) and lowest percentage from women (8,28%). These data upon the references resulted as hyperglycaemia were compared to COVID-19 vaccinated patients with normoglycemia blood glucose measures. So, our study dataset was a backward-looking study which the glucose parameter listed in the electronic medical records could be analyzed as focuses the predictor factor on vaccinated patients against SARS-CoV-2. We concluded that new insulin therapy could be applied in future studies including diabetic patients vaccinated against COVID-19. It is also added that comorbidities were not considered in the analysis of controlled glucose levels and/or considered within the normal reference standard.